Gilead Sciences Inc.

Foster City, CA, United States

Gilead Sciences Inc.

Foster City, CA, United States

Time filter

Source Type

Patent
Gilead Sciences Inc. | Date: 2017-04-26

Compounds of Formula (IV), as well as pharmaceutically acceptable salts thereof, are disclosed:


Patent
Gilead Sciences Inc. | Date: 2017-02-08

Compounds of the form in which Q is selected from -COOH -CH=NR12, -W, -CH2NHR13, -CH=0 and -CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.


Patent
Gilead Sciences Inc. | Date: 2017-02-03

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.


Patent
Gilead Sciences Inc. | Date: 2017-05-17

Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR7, including those of Formula (II); and pharmaceutically acceptable salts thereof, useful in treating HIV infections.


The present Invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10 -((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1,2:4,5] pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.


Ethyl 2-{[({[2-(dimethylamino)ethyl](ethyl)carbamoyl}methyl)amino]methyl}pyridine-4-carboxylate


Patent
Gilead Sciences Inc. | Date: 2017-05-24

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease slates, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.


The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4- morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.


Patent
Gilead Sciences Inc. | Date: 2017-04-19

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3 -kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.


Patent
Gilead Sciences Inc. | Date: 2017-06-28

Provided herein are formulations, methods and substituted 2-chloro aminopyrimidinone and pyrimidine dione compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of substituted 2-chloro aminopyrimidinone and pyrimidine dione compounds.

Loading Gilead Sciences Inc. collaborators
Loading Gilead Sciences Inc. collaborators